# Jnana Therapeutics

**Canonical:** https://apis.io/providers/jnana-therapeutics/  
**Website:** https://www.jnanatx.com/  
**APIs profiled:** 1

Jnana Therapeutics Inc. is a biotechnology company headquartered at One Design Center Place, Suite 19-400, Boston, Massachusetts, that built RAPID — Reactive Affinity Probe Interaction Discovery — a next-generation chemoproteomics platform for discovering small-molecule medicines against target classes that conventional screening has struggled to drug, including SLC transporters, transcription factors, signaling scaffold proteins, phosphatases, GPCRs and helicases. RAPID runs in living cells: a proprietary Reactive Affinity Probe library covalently labels druggable pockets on a validated target, and a proprietary detection technology then screens large drug-like compound libraries for binders that displace the probe, yielding allosteric inhibitors, localization modulators and molecular glues without iterative structural biology. Its internal pipeline focuses on phenylketonuria (PKU) — where JNT-517, an oral inhibitor acting at a cryptic allosteric site on the SLC6A19 transporter, reached Phase 1b/2 — and on immune-mediated diseases including targets such as interferon regulatory factor 3 (IRF3), alongside biopharma collaborations that include Roche. Otsuka Pharmaceutical Co., Ltd. completed its acquisition of Jnana on 23 September 2024 for $800 million plus up to $325 million in development and regulatory milestones, making Jnana a direct subsidiary of Otsuka America, Inc.; Otsuka initiated a global Phase 3 trial of repinatrabit in PKU in December 2025. Jnana Therapeutics runs no developer program and publishes no product API, developer portal, API reference or SDK. The only machine-readable surface reachable without credentials is the WordPress REST content API behind www.jnanatx.com, catalogued here.

## Kin Score — 30.3 / 100 (thin)

Scored 2026-08-25 under rubric 0.14.0. Trend: flat (-0.7 from 31.0).

| Facet | Score |
|---|---|
| Discoverability | 68.5 |
| Contract Quality | 50.3 |
| Governance | 16.7 |
| Contract Governance | 16.7 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 13.7 |
| Commercial Clarity | 21.1 |
| Access Clarity | 21.1 |

Regulatory layer — **Health**: 31.3 (matched via tags).

## Agent readiness — 21.8 (agent-aware)

| Dimension | Value |
|---|---|
| Spec Presence | yes |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | bearer |
| Idempotency | no |
| Error Semantics | documented |
| OpenAPI Examples | no |
| Rate Limit Signal | documented |
| Event Surface Described | no |
| Agent Skills | derived |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |

## APIs (1)

- **Jnana Therapeutics Content API** — The read-only WordPress REST content surface behind www.jnanatx.com — news posts (62), corporate pages (9), media (376), post categories (7), the `team` custom post type (9 prof...

## Security (2)

- **Jnana Therapeutics Authentication** — 2 schemes
- **Jnana Therapeutics Domain Security** — TLSv1.3 · HSTS · DMARC

## Plans (1)

- **Jnana Therapeutics Plans Pricing**

## Tags

Company, Biotechnology, Pharmaceuticals, Drug Discovery, Chemoproteomics, Rare Disease, Immunology, Life Sciences, Clinical Trials, content-api

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/jnana-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.